Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Weight Management in Women of Reproductive Age

Jarrod Warner & Irene Schneider

Jarrod Warner & Irene Schneider

New Spirometry Standards: Key Changes for Clinical Practice

A/Prof Alberto Pinzon Charry

A/Prof Alberto Pinzon Charry

Food Allergy Prevention

A/Prof Daryl Cheng

A/Prof Daryl Cheng

Protecting Young Lungs – Paediatric Insights into RSV

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023